Cafe au Lait Spots Linked to Early-Onset Colorectal Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

ORLANDO-Researchers from the Johns Hopkins University Hereditary Colorectal Cancer Registry have identified what they believe is a previously unrecognized hereditary cancer syndrome. Patients with this syndrome, a variant of hereditary nonpolyposis colorectal cancer (HNPCC), exhibit cafe au lait spots and develop their malignancies at a much earlier age than do other HNPCC patients.

ORLANDO—Researchers from the Johns Hopkins University Hereditary Colorectal Cancer Registry have identified what they believe is a previously unrecognized hereditary cancer syndrome. Patients with this syndrome, a variant of hereditary nonpolyposis colorectal cancer (HNPCC), exhibit cafe au lait spots and develop their malignancies at a much earlier age than do other HNPCC patients.

These pigmented lesions have not previously been considered an extracolonic manifestation of hereditary colorectal cancer, although there have been reports of the combination in the literature. (Cafe au lait spots have long been considered a classic manifestation of neurofibromatosis.) Jill Brensinger, MS, CGC, a genetic counselor at Johns Hopkins, presented a poster on the research during the Digestive Disease Week meeting.

“We happened upon two families with cafe au lait spots and very-early-onset colon cancer,” Ms. Brensinger said. “We then decided to search the literature for other families that were affected by cafe au lait spots and either colon polyps or cancer.” The search identified 25 such families.

The researchers then compared those 25 families with 55 families with colon polyps and/or cancer and no cafe au lait spots. The mean age of the onset of colorectal adenomas in the families with cafe au lait spots was 15.7 years, while in families without cafe au lait spots, it was 23.6 years (P = .003).

Oligopolyposis More Likely

In families with cafe au lait spots, individuals with polyps were far more likely to exhibit oligopolyposis (less than 100 polyps) when they had their first colorectal examination rather than the polyposis (100 or more polyps) that was more typical of the families without cafe au lait spots (P < .001).

Also, families with cafe au lait spots were far more likely to have brain tumors diagnosed at a young age (P = .01). Almost half (46.7%) of the people affected by cancer in the families with cafe au lait spots had brain tumors, and they were diagnosed at a mean age of 16.5 years.

Ms. Brensinger also reported that the colorectal cancer patients with cafe au lait spots ran an increased risk of hematologic malignancies.

Mismatch Repair Gene Mutations

The researchers believe that a mutation of the mismatch repair genes PMS2 or MLH1 may cause the newly identified syndrome. They suggest that germ-line testing for mutations in these two genes, and perhaps other mismatch repair genes, may help in the surveillance of families with cafe au lait spots and early-onset colorectal neoplasia.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Related Content